Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : CELSION CORP. (CLN was CELN) UP $.33 TO $.59 ON HUGE NEWS -- Ignore unavailable to you. Want to Upgrade?

To: Dave Gore who wrote (221)	1/31/1999 1:49:00 PM
From: Deeber	Respond to of 518

I do think CELN will have a good week though, there seems to be a nice base forming at the $1 range, so in my opinion the upsiude potential here FAR outweighs the downside. I know I would like to add some shares Monday if it does not gap too much at the open. Hopefully there will be more news released this week too, possibly on this financing.

To: Dave Gore who wrote (221)	1/31/1999 1:56:00 PM
From: Larry Brew	Read Replies (1) \| Respond to of 518

Dave, I believe you are very wrong with your assumption it's not a human study. Where did you learn Phase one does not involve humans. You and I can make non human tissue study without any approval. I believe the term 'clinical' below covers it. I've seen other press where it's on advanced cases I believe. Now I have to find it to substantiate what I believe a wrong assumption on your part. Larry I skip a lot, but I'm not skipping the superbowel. Thanks for saving us. See you Monday! The IDE approval enables Celsion to proceed with phase one clinical studies for its non-surgical, minimally-invasive system which utilizes focused heat alone to kill cancerous tumors in the breast. PRECLINICAL studies have indicated the possibility that the treatment will be non-toxic and side-effect-free.